These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16430192)

  • 1. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Crusat M; de Jong MD
    Antivir Ther; 2007; 12(4 Pt B):593-602. PubMed ID: 17944267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir resistance in influenza A (H5N1) infection.
    Gupta RK; Nguyen-Van-Tam JS
    N Engl J Med; 2006 Mar; 354(13):1423-4; author reply 1423-4. PubMed ID: 16571890
    [No Abstract]   [Full Text] [Related]  

  • 6. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral management of seasonal and pandemic influenza.
    Hayden FG; Pavia AT
    J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
    de Jong JC; Beyer WE; Rimmelzwaan GF; Fouchier RA; Osterhaus AD
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):73-9. PubMed ID: 14753128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral agents for influenza].
    Mitamura K
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():798-803. PubMed ID: 12722319
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
    Lackenby A; Democratis J; Siqueira MM; Zambon MC
    Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors].
    Reina J
    Rev Esp Quimioter; 2008 Mar; 21(1):32-6. PubMed ID: 18443931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Critical review of anti-influenza drugs].
    van Loon FP; Voordouw AC; Simonian S; Koopmans PP
    Ned Tijdschr Geneeskd; 2000 Jan; 144(4):165-7. PubMed ID: 10668542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir resistance--disabling our influenza defenses.
    Moscona A
    N Engl J Med; 2005 Dec; 353(25):2633-6. PubMed ID: 16371626
    [No Abstract]   [Full Text] [Related]  

  • 18. Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.
    Li J; Zheng M; Tang W; He PL; Zhu W; Li T; Zuo JP; Liu H; Jiang H
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5009-13. PubMed ID: 16876409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antivirals and influenza: frequency of resistance.
    Monto AS
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.